Answers are grounded in this paper and cite their sources.
New therapeutic strategies are now considered in acute myelogenous leukemia (AML), including the use of histone deacetylase (HDAC) inhibitors, all-trans retinoic acid (ATRA) and the cyclic AMP incr...
No takes yet. Share an insight, caveat, or question.
Stapnes et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: